AIMS: To evaluate the efficacy and toxicity of extracranial stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic lymph node involvement in the mediastinum, retroperitoneum, or pelvis, in a consecutive group of patients from real clinical practice outside clinical trials. METHODS: A retrospective analysis of 90 patients with a maximum of four oligometastases and various primary tumors (the most common being colorectal cancers). The endpoints were local control of treated metastases (LC), freedom from widespread dissemination (FFWD), progression-free survival (PFS), overall survival (OS), and freedom from systemic treatment (FFST). Acute and delayed toxicities were also evaluated. RESULTS: The median follow-up after SBRT was 34.9 months. The LC rate at three and five years was 68.4 and 56.3%, respectively. The observed median FFWD was 14.6 months, with a five-year FFWD rate of 33.7%. The median PFS was 9.4 months; the three-year PFS rate was 19.8%. The median FFST was 14.0 months; the five-year FFST rate was 23.5%. The OS rate at three and five years was 61.8 and 39.3%, respectively. Median OS was 53.1 months. The initial dissemination significantly shortened the time to relapse, death, or activation of systemic treatment-LC (HR 4.8, p < 0.001), FFWD (HR 2.8, p = 0.001), PFS (HR 2.1, p = 0.011), FFST (HR 2.4, p = 0.005), OS (HR 2.2, p = 0.034). Patients classified as having radioresistant tumors noticed significantly higher risk in terms of LC (HR 13.8, p = 0.010), FFWD (HR 3.1, p = 0.006), PFS (HR 3.5, p < 0.001), FFST (HR 3.2, p = 0.003). The multivariable analysis detected statistically significantly worse survival outcomes for initially disseminated patients as well as separately in groups divided according to radiosensitivity. No grade III or IV toxicity was reported. CONCLUSION: Our study shows that targeted SBRT is a very effective and low toxic treatment for oligometastatic lymph node involvement. It can delay the indication of cytotoxic chemotherapy and thus improve and maintain patient quality of life. The aim of further studies should focus on identifying patients who benefit most from SBRT, as well as the correct timing and dosage of SBRT in treatment strategy.

Central European Institute of Technology Masaryk University Brno Czechia

Department of Nuclear Medicine and PET Center Masaryk Memorial Cancer Institute Brno Czechia

Department of Radiation Oncology Faculty of Medicine Masaryk University Brno Czechia

Department of Radiation Oncology Masaryk Memorial Cancer Institute Brno Czechia

Research Center for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czechia

Zobrazit více v PubMed

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol (2020) 148:157–66.  10.1016/j.radonc.2020.04.003 PubMed DOI

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol (1995) 13:8–10.  10.1200/JCO.1995.13.1.8 PubMed DOI

Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol (2011) 8:378–82.  10.1038/nrclinonc.2011.44 PubMed DOI

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol (2020) 38:2830–8.  10.1200/JCO.20.00818 PubMed DOI PMC

Niibe Y, Hayakawa K. Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy. Jpn J Clin Oncol (2010) 40:107–11.  10.1093/jjco/hyp167 PubMed DOI PMC

Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, et al. Clinical Outcome of Hypofractionated Stereotactic Radiotherapy for Abdominal Lymph Node Metastases. Int J Radiat Oncol (2011) 81:831–8.  10.1016/j.ijrobp.2010.05.032 PubMed DOI

Burkoň P, Slávik M, Kazda T, Pospíšil P, Procházka T, Vrzal M, et al. Stereotactic Body Radiotherapy – Current Indications. Klin Onkol (2019) 32:10–24.  10.14735/amko201910 PubMed DOI

Chang JS, Sethi RA, Barani IJ. Extracranial Oligometastases. In Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy. Cham: Springer International Publishing; (2016). pp. 203–20. 10.1007/978-3-319-21897-7_12 DOI

Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018. J Natl Compr Cancer Netw (2018) 16:807–21.  10.6004/jnccn.2018.0062 PubMed DOI

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2017) 28:iv1–iv21.  10.1093/annonc/mdx222 PubMed DOI

Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol (2017) 7:295–301.  10.1016/j.prro.2017.04.014 PubMed DOI

Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol (2013) 14:e28–37.  10.1016/S1470-2045(12)70510-7 PubMed DOI

Corbin KS, Hellman S, Weichselbaum RR. Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy. J Clin Oncol (2013) 31:1384–90.  10.1200/JCO.2012.45.9651 PubMed DOI

Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiat Oncol (2018) 102:S3–4.  10.1016/j.ijrobp.2018.06.105 DOI

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, DeSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol (2020) 21:e18–28.  10.1016/S1470-2045(19)30718-1 PubMed DOI

Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, et al. The NOMS Framework: Approach to the Treatment of Spinal Metastatic Tumors. Oncologist (2013) 18:744–51.  10.1634/theoncologist.2012-0293 PubMed DOI PMC

Spratt DE, Beeler WH, de Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, et al. An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. Lancet Oncol (2017) 18:e720–30.  10.1016/S1470-2045(17)30612-5 PubMed DOI

McPherson CM, Suki D, Feiz-Erfan I, Mahajan A, Chang E, Sawaya R, et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro Oncol (2010) 12:711–9.  10.1093/neuonc/noq005 PubMed DOI PMC

Paterson R. Classification of Tumours in Relation to Radiosensitivity. Br J Radiol (1933) 6:218–33.  10.1259/0007-1285-6-64-218 DOI

Burkon P, Slampa P, Kazda T, Slavik M, Prochazka T, Vrzal M. Stereotactic body radiation therapy for colorectal cancer liver metastases; early results. Klin Onkol (2012) 25(Suppl 2):2S93–7. 10.14735/amko20122S93 PubMed

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol (2005) 63:1427–31.  10.1016/j.ijrobp.2005.05.034 PubMed DOI

Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, et al. Four-Dimensional Computed Tomography Scan Analysis of Tumor and Organ Motion at Varying Levels of Abdominal Compression During Stereotactic Treatment of Lung and Liver. Int J Radiat Oncol (2008) 70:1571–8.  10.1016/j.ijrobp.2007.12.023 PubMed DOI

Josipovic M, Persson GF, Bangsgaard JP, Specht L, Aznar MC. Deep inspiration breath-hold radiotherapy for lung cancer: impact on image quality and registration uncertainty in cone beam CT image guidance. Br J Radiol (2016) 89(1068):20160544.  10.1259/bjr.20160544 PubMed DOI PMC

Nagata Y, Wulf J, Lax I, Timmerman R, Zimmermann F, Stojkovski I, et al. Stereotactic Radiotherapy of Primary Lung Cancer and Other Targets: Results of Consultant Meeting of the International Atomic Energy Agency. Int J Radiat Oncol (2011) 79:660–9.  10.1016/j.ijrobp.2010.10.004 PubMed DOI

Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S. Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer. Int J Radiat Oncol (2008) 70:685–92.  10.1016/j.ijrobp.2007.10.053 PubMed DOI

Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys (2010) 37:4078–101.  10.1118/1.3438081 PubMed DOI

Ong CL, Verbakel WFAR, Cuijpers JP, Slotman BJ, Lagerwaard FJ, Senan S. Stereotactic radiotherapy for peripheral lung tumors: A comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol (2010) 97:437–42.  10.1016/j.radonc.2010.09.027 PubMed DOI

Purdie TG, Bissonnette J-P, Franks K, Bezjak A, Payne D, Sie F, et al. Cone-Beam Computed Tomography for Online Image Guidance of Lung Stereotactic Radiotherapy: Localization, Verification, and Intrafraction Tumor Position. Int J Radiat Oncol (2007) 68:243–52.  10.1016/j.ijrobp.2006.12.022 PubMed DOI

Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer/Radiothérapie (2011) 15:555–9.  10.1016/j.canrad.2011.04.003 PubMed DOI

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45:228–47.  10.1016/j.ejca.2008.10.026 PubMed DOI

van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2010) 20:1456–67.  10.1007/s00330-009-1685-y PubMed DOI PMC

R Core Team R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; (2020). Available at: https://www.R-project.org/.

Seuntjens J, Lartigau E, Cora S. ICRU Report 91. Prescribing, recording, and reporting of stereotactic treatments with small photon beams. J ICRU (2014) 14:1–160.  10.1093/jicru/ndx009 PubMed DOI

van Gestel YRBM, de Hingh IHJT, van Herk-Sukel MPP, van Erning FN, Beerepoot LV, Wijsman JH, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol (2014) 38:448–54.  10.1016/j.canep.2014.04.004 PubMed DOI

Todo Y, Kato H, Minobe S, Okamoto K, Suzuki Y, Sudo S, et al. Initial failure site according to primary treatment with or without para-aortic lymphadenectomy in endometrial cancer. Gynecol Oncol (2011) 121:314–8.  10.1016/j.ygyno.2011.01.019 PubMed DOI

Shibata D, Paty PB, Guillem JG, Wong DW, Cohen AM. Surgical Management of Isolated Retroperitoneal Recurrences of Colorectal Carcinoma. Dis Colon Rectum (2002) 45:795–801.  10.1007/s10350-004-6300-3 PubMed DOI

Jereczek-Fossa BA, Ronchi S, Orecchia R. Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother (2015) 20:472–83.  10.1016/j.rpor.2014.10.004 PubMed DOI PMC

Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, et al. Linac-based Stereotactic Body Radiotherapy for Oligometastatic Patients With Single Abdominal Lymph Node Recurrent Cancer. Am J Clin Oncol (2014) 37:227–33.  10.1097/COC.0b013e3182610878 PubMed DOI

Yeung R, Hamm J, Liu M, Schellenberg D. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol (2017) 12:105.  10.1186/s13014-017-0820-1 PubMed DOI PMC

Loi M, Frelinghuysen M, Klass ND, Oomen-De Hoop E, Granton PV, Aerts J, et al. Locoregional control and survival after lymph node SBRT in oligometastatic disease. Clin Exp Metastasis (2018) 35:625–33.  10.1007/s10585-018-9922-x PubMed DOI PMC

Franzese C, Badalamenti M, Comito T, Franceschini D, Clerici E, Navarria P, et al. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment’s intensification? Radiother Oncol (2020) 150:184–90.  10.1016/j.radonc.2020.06.029 PubMed DOI

Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, et al. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clin Genitourin Cancer (2017) 15:e623–32.  10.1016/j.clgc.2017.01.004 PubMed DOI

Wang Z, Wang J, Zhuang H, Wang P, Yuan Z. Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis. Sci Rep (2016) 6:37987.  10.1038/srep37987 PubMed DOI PMC

Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, et al. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (2016) 28:e115–20.  10.1016/j.clon.2016.04.040 PubMed DOI

Choi CW, Cho CK, Yoo SY, Kim MS, Yang KM, Yoo HJ, et al. Image-Guided Stereotactic Body Radiation Therapy in Patients With Isolated Para-Aortic Lymph Node Metastases From Uterine Cervical and Corpus Cancer. Int J Radiat Oncol (2009) 74:147–53.  10.1016/j.ijrobp.2008.07.020 PubMed DOI

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol (2011) 81:1352–8.  10.1016/j.ijrobp.2009.07.1751 PubMed DOI

Winkel D, Bol GH, Werensteijn-Honingh AM, Intven MPW, Eppinga WSC, Hes J, et al. Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment. Radiother Oncol (2020) 146:118–25.  10.1016/j.radonc.2020.02.011 PubMed DOI

Winkel D, Bol GH, Werensteijn-Honingh AM, Kiekebosch IH, van Asselen B, Intven MPW, et al. Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance. Phys Imaging Radiat Oncol (2019) 9:58–64.  10.1016/j.phro.2019.02.003 PubMed DOI PMC

Werensteijn-Honingh AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B, Bol GH, et al. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. Radiother Oncol (2019) 134:50–4.  10.1016/j.radonc.2019.01.024 PubMed DOI

Burkon P, Kazda T, Pospisil P, Slavik M, Kominek L, Selingerova I, et al. Ablative dose stereotactic body radiation therapy for oligometastatic disease: A prospective single institution study. Neoplasma (2019) 66(2):315–25.  10.4149/neo_2018_180731N558 PubMed DOI

Matsushita H, Jingu K, Umezawa R, Yamamoto T, Ishikawa Y, Takahashi N, et al. Stereotactic Radiotherapy for Oligometastases in Lymph Nodes—A Review. Technol Cancer Res Treat (2018) 17153303381880359.  10.1177/1533033818803597. 153303381880359. PubMed DOI PMC